The Company and Summary of Significant Accounting Policies (Details Textual)		3 Months Ended	9 Months Ended
	Jun. 16, 2015 USD ($)	Mar. 31, 2017 Patients	Sep. 30, 2016 USD ($) Patients
Company And Summary Of Significant Accounting Policies Table [Line Items]
Revenues | $			$ 0
Concentrations of credit risk | $			$ 0
Private Investment In Public Entity Transaction
Company And Summary Of Significant Accounting Policies Table [Line Items]
Proceeds from the issuance of security units | $	$ 34,200,000
Phase 3 heart failure (HF) trial of Gencaro | BEST Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients | Patients			2,708
Phase 2B/Phase 3 | GENETIC-AF Trial
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients company plans to enroll | Patients			620
Trial endpoint, term			168 days
Phase 2B | GENETIC-AF Trial | Forecast
Company And Summary Of Significant Accounting Policies Table [Line Items]
Number of patients company plans to enroll | Patients		150